PDCD1LG2 and neoplasm: Although not all tumor mice displayed responses to monotherapy to anti‐PD‐1/PD‐L1, the PD‐L2/RGMb pathway intervention via manipulating gut microbiota exhibits anti‐tumor immunity responses, which warrants further study to validate in clinical trials.